SCHEMBL1750508

SCHEMBL1750508

CC(=O)NCCc1ccc(Cl)c(CO[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
PTGS1 P23219 1/20 0.46
BLM P54132 1/20 0.46
HIF1A Q16665 1/20 0.46
HSD17B10 Q99714 1/20 0.46
F13A1 P00488 1/20 0.46
MTNR1A P48039 4/20 0.44
MTNR1B P49286 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
ESRRB O95718 1/20 0.39
ESRRG P62508 1/20 0.39
RAF1 P04049 2/20 0.39
TRPV1 Q8NER1 1/20 0.38
ACACB O00763 1/20 0.38
NQO2 P16083 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089007 0.91 TSHR (0.43) ALDH1A1LMNASMN1; SMN2ESRRBESRRG
SCHEMBL1751532 0.88 TSHR (0.45) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL3074349 0.85 REN (0.40) ESRRBESRRGRAF1TRPV1
SCHEMBL3075604 0.85 HTR1A (0.41) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL3085746 0.83 HTR1A (0.44)
SCHEMBL1751379 0.82 FFAR1 (0.34) KDM4EALDH1A1MAPTTRPV1
SCHEMBL1750278 0.81 TSHR (0.58) ALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL1751171 0.80 KDM4E (0.39) KDM4EALDH1A1LMNASMN1; SMN2ESRRB
SCHEMBL662526 0.80 TAAR1 (0.46) KDM4ELMNASMN1; SMN2
SCHEMBL661775 0.79 USP14 (0.35) MAPTHPGDHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968720-B2 Secondary amines as renin inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2011-06-28 US disclosed
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES BEZENCON OLIVIER 2010-12-23 US disclosed
US-7799805-B2 Piperidine carboxylic acid amide derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-21 US disclosed
US-20090176823-A1 Secondary Amines as Renin Inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2009-07-09 US disclosed
EP-1981847-A1 SECONDARY AMINES AS RENIN INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2008-10-22 EP disclosed
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives ACTELION PHARMACEUTICALS LTD (CH) 2008-09-04 US disclosed
WO-2007088514-A1 SECONDARY AMINES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives REN, ACE, AGTR2 KDM4E 1024/4885ALDH1A1 387/4885LMNA 3198/4885
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES REN, ACE, AGTR2 KDM4E 853/4885ALDH1A1 313/4885LMNA 2841/4885
US-20090176823-A1 Secondary Amines as Renin Inhibitors REN, ACE, AGTR1 KDM4E 2489/4885ALDH1A1 941/4885LMNA 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.